Characteristics of HSCT
| Transplant characteristics . | Total patient number n = 60 . |
|---|---|
| Median year of HSCT (range) | 2014 (2004-2019) |
| Median age at HSCT, y (range) | 3.4 (0.3-42.9) |
| Age < 3.5 | 31 (52) |
| Age ≥ 3.5 | 29 (48) |
| Donor, n (%) | |
| MSD or MFD | 13 (22) |
| MMFD | 11 (18) |
| MUD | 29 (48) |
| MMUD | 7 (12) |
| Graft, n (%) | |
| Bone marrow | 35 (58) |
| Cord blood | 7 (12) |
| PBSC | 18 (30) |
| In vitro T-cell depletion, n (%) | 15 (25) |
| CR, n (%) | |
| MAC | 19 (32) |
| RIC | 18 (30) |
| RTC | 22 (37) |
| Serotherapy, n (%) | |
| ATG | 32 (53) |
| Alemtuzumab | 17 (28) |
| Transplant characteristics . | Total patient number n = 60 . |
|---|---|
| Median year of HSCT (range) | 2014 (2004-2019) |
| Median age at HSCT, y (range) | 3.4 (0.3-42.9) |
| Age < 3.5 | 31 (52) |
| Age ≥ 3.5 | 29 (48) |
| Donor, n (%) | |
| MSD or MFD | 13 (22) |
| MMFD | 11 (18) |
| MUD | 29 (48) |
| MMUD | 7 (12) |
| Graft, n (%) | |
| Bone marrow | 35 (58) |
| Cord blood | 7 (12) |
| PBSC | 18 (30) |
| In vitro T-cell depletion, n (%) | 15 (25) |
| CR, n (%) | |
| MAC | 19 (32) |
| RIC | 18 (30) |
| RTC | 22 (37) |
| Serotherapy, n (%) | |
| ATG | 32 (53) |
| Alemtuzumab | 17 (28) |
ATG, anti-thymocyte globulin.